Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559713 | 0.89 | CHEK1 (0.46) | HTR3ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2803334 | 0.86 | SLC18A3 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4HRH3 | |
| Hydrochloric Acid SCHEMBL4463792 | 0.84 | SLC18A3 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4HRH3 | |
| SCHEMBL7895339 | 0.81 | CHRNB2 (0.39) | HTR3ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL3001216 | 0.79 | CHRNB2 (0.38) | HTR3ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL3716821 | 0.79 | CHRNB2 (0.38) | HTR3ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2282526 | 0.79 | HTR3A (0.44) | HTR3A | |
| SCHEMBL19566656 | 0.79 | CYP11B2 (0.62) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL717702 | 0.79 | CYP11B2 (0.62) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL12954652 | 0.78 | HTR3A (0.47) | HTR3AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604191-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine | TARGACEPT, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20110281895-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281895-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | HTR3A 3580/4885CHRNB2 4220/4885CHRNB4 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.